|
A.Yu. Nikolaeva, O.A. Bitkina, I.V. Kosheleva, M.V. Presnyakova, K.N. Kontorshchikova, A.A. Dmitrieva, P.V. Peretyagin, A.A. Tsyganova
Postcovid alopecia: from the study of pathogenesis to the choice of therapy
|
№8 / 2023
|
|
O.V. Maksim, B.V. Romashevsky, N.Yu. Demyanenko
Features of the pathogenesis of thyroid diseases in COVID-19
|
№3 / 2023
|
|
S.V. Nikolaeva, E.K. Shushakova
Respiratory infections during the COVID-19 pandemic – what has changed?
|
№1-2 / 2023
|
|
I.S. Vladimirova
Psoriasis, metabolic syndrome and COVID-19: a case report
|
№14 / 2022
|
|
R.A. Bontsevich, Ya.R. Vovk, V.A. Vinyukov, D.G. Dubonosova
Preferences of Belgorod primary care phycisians in the treatment of a new coronavirus infection
|
№10 / 2022
|
|
O.A. Bashkina, I.V. Vyazovaya, D.F. Sergienko
Pediatric inflammatory multisystem syndrome associated with COVID-19: a clinical case
|
№9 / 2022
|
|
A.A. Turovskaya, E.M. Kostina, E.A. Orlova, E.Yu. Trushina, G.M. Grishanovich, O.G. Sidorova, E.V. Avdoshina
Features of the clinical course of a new coronavirus infection in children
|
№9 / 2022
|
|
A.A. Astapovsky, V.N. Drozdov, E.V. Shikh, N.B. Lazareva, G.G. Melkonyan, A.A. Meshcheryakov, E.V. Tsepkova
Proadrenomedullin levels and clinical features of SARS-CoV-2 coronavirus infection: a prospective clinical study
|
№5 / 2022
|
|
N.V. Izmozherova, A.A. Popov, I.P. Antropova, L.I. Kadnikov, Ya.V. Livshits, A.D. Kushtyeva, A.A. Nikonova, V.M. Bakhtin, M.A. Shambatov
Exogenous glucocorticoids and the platelet component of the hemostasis system in COVID-19
|
№5 / 2022
|
|
I.B. Zhurtova, M.A. Elgarova, A.M. Gubachikova, M.R. Kurashinova
Manifestation of primary adrenal insufficiency in a child against the background of a novel coronovirus infection COVID-19: a clinical case
|
№1 / 2022
|
|
A.I. Tarzimanova, E.E. Bykova
Antiarrhythmic therapy for atrial fibrillation in patients with the novel SARS-CoV-2 coronavirus infection: how to make the right choice?
|
№13 / 2021
|
|
V.M. Tsvetov (1), I.S. Burashnikova (2), D.A. Sychev (3)
Possibility and prospects for the use of recombinant neutralizing monoclonal antibodies (bamlanivimab+etesevimab, sotrovimab) in patients with COVID-19
|
№12 / 2021
|
Русский
